Development of CD39 as a therapy for stroke
Development of CD39 as a therapy for stroke
The brain is detrimentally affected after stroke and cardiac arrest. The aim of this thesis was to demonstrate that the novel drug from our lab - αVCAM-CD39 will improve neurological outcome in mouse models of stroke and cardiac arrest. We found that post- αVCAM-CD39 treatment, there was significant protection in the brain, and we showed that our compound was able to significantly reduced stroke-related injury, such as reduced tissue damage and cell death. We were able to confirm that αVCAM-CD39 could be a new avenue of stroke therapy and could potentially be used in other similar diseases.
Cardiovascular medicine and haematology not elsewhere classified, Neurosciences not elsewhere classified
Cardiovascular medicine and haematology not elsewhere classified, Neurosciences not elsewhere classified
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!